NEW YORK, March 2, 2017 /PRNewswire/ --
On Wednesday, March 01, 2017, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Eight out of nine sectors ended Wednesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, Stock-Callers.com assessed the following Drugs - Generic equities this morning: Diplomat Pharmacy Inc. (NYSE: DPLO), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), Agile Therapeutics Inc. (NASDAQ: AGRX), and Sophiris Bio Inc. (NASDAQ: SPHS). Download the free research reports on these stocks today:
Flint, Michigan headquartered Diplomat Pharmacy Inc.'s stock finished Wednesday's session 10.11% higher at $14.92 with a total volume of 3.86 million shares traded. Diplomat Pharmacy's shares have gained 12.35% in the past one month. The Company's shares are trading above its 50-day moving average by 8.36%. Shares of Diplomat Pharmacy, which operates as an independent specialty pharmacy in the US, are trading at a PE ratio of 30.64. The stock has a Relative Strength Index (RSI) of 57.39. See our free and comprehensive research report on DPLO at:
Cambridge, Massachusetts headquartered Momenta Pharmaceuticals Inc.'s stock fell 2.27%, to close the day at $15.10. The stock recorded a trading volume of 1.06 million shares, which was above its three months average volume of 725,150 shares. Momenta Pharma's shares have surged 8.63% in the previous three months and 76.61% in the past one year. The Company's shares are trading 15.82% above its 200-day moving average. Shares of the Company, which focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases, have an RSI of 36.92.
On February 22nd, 2017, research firm Leerink Partners downgraded the Company's stock rating from 'Outperform' to 'Market Perform'. MNTA free research report PDF is just a click away at:
On Wednesday, shares in Princeton, New Jersey headquartered Agile Therapeutics Inc. ended the session 0.90% lower at $2.20 with a total volume of 130,458 shares traded. The stock is trading 33.87% below its 50-day moving average and 64.71% below its 200-day moving average. Moreover, shares of the Company, which focuses on the development and commercialization of prescription contraceptive products for women, have an RSI of 25.57. Sign up for your complimentary report on AGRX at:
On Wednesday, shares in La Jolla, California-based Sophiris Bio Inc. recorded a trading volume of 248,530 shares. The stock ended the day 0.76% lower at $2.66. Sophiris Bio's stock has surged 51.14% in the past one year. The Company is trading below its 50-day and 200-day moving averages by 5.79% and 7.77%, respectively. Furthermore, shares of Sophiris Bio, which focuses on the development of products for the treatment of urological diseases, have an RSI of 43.09. Register for free on Stock-Callers.com and download the latest research report on SPHS at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA